PARP1 and colitis: On the contrary, inhibition of poly(ADP-ribosyl)ation preserves the cellular energy pool, thus preventing metabolic failure and providing cytoprotection, and previous in vivo studies demonstrated that genetic ablation of PARP-1 ameliorates the pathophysiological changes of experimental colitis [12].